DR. ANUBHAV GOYAL

DR. JIZ MARY SANTHOSH, DR.A. GIRIDHAR, DR. G. MAHESH

Abstract

Purpose: To investigate the effect of aflibercept (Eylea) and brolucizumab (pagenax) in eyes refractive to multiple treatments of bevacizumab and/or ranibizumab in nAMD.

Methods: SD-OCT and BCVA data were investigated in 31 eyes with recalcitrant nAMD were retrospectively analysed in treatment was switched to aflibercept or brolucizumab- at initial diagnosis of nAMD (I), at switch to brolucizumab or alfibercept (II), 4 weeks after switched injection (III) till last followup after switching injection.

Results: After switching to brolucizumab or aflibercept, significant reduction seen in central retinal thickness (CRT, p = 0.001), SRF (p = 0.004) and sub-RPE fluid (p = 0.04), but no significant BCVA improvement (p = 0.767). Complete drying of macula after switching injections was seen in 48.38% eyes.

Conclusion: Intravitreal aflibercept and/or brolucizumab treatment can achieve significant macula drying in patients refractory to previous anti-VEGF treatment.